Get started
Author

Jing Yu

Observed names: J Yu, Yu Jing, Yu, Jing, 余静
Observed institutions: Cedars-Sinai Medical Center, Dartmouth–Hitchcock Medical Center, Beijing Tongren Hospital, Harvard University, Army Medical University, Sun Yat-sen University, Shanghai Jiao Tong University, Capital Medical University, Hong Kong University of Science and Technology, University of Michigan, Huzhou Normal University, Sixth Affiliated Hospital of Sun Yat-sen University, Second Hospital of Hebei Medical University, Novo Nordisk (United States), Michigan Medicine, Tongren University, Chengdu Center for Disease Control and Prevention, Wenzhou City People's Hospital, Nanchong Central Hospital, Salix Pharmaceuticals (United States), Qiqihar Medical University
ORCID: 0009-0007-9616-1157
Observed ORCID: 0009-0007-9616-1157
OpenAlex ID: A5102190546
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
2011 · Mark Pimentel, Anthony Lembo, et al. · New England Journal of Medicine · 1,036
PDF
Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution
2024 · Xuechao Liu, Jing Yu, et al. · Cell Death and Disease · 30
PDF
From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics
2011 · Jing Yu, Helene Karcher, et al. · The AAPS Journal · 29
PDF
Modeling Viral Kinetics and Treatment Outcome During Alisporivir Interferon-Free Treatment in Hepatitis C Virus Genotype 2 and 3 Patients
2013 · Jeremie Guedj, Jing Yu, et al. · Hepatology · 28
A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy Volunteers
2016 · Kiran Dole, Florencia Pereyra Segal, et al. · Antimicrobial Agents and Chemotherapy · 26
Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model
2014 · Suresh B. Lakshminarayana, Céline Freymond, et al. · Antimicrobial Agents and Chemotherapy · 17
PDF
[Clinical characteristics of Henoch-Schönlein purpura in children].
2015 · Li-Jun Liu, Jing Yu, et al. · PubMed · 14
475i Rifaximin Treatment for 2 Weeks Provides Acute and Sustained Relief Over 12 Weeks of IBS Symptoms in Non-Constipated Irritable Bowel Syndrome: Results From 2 North American Phase 3 Trials (Target 1 and Target 2)
2010 · Mark Pimentel, Anthony Lembo, et al. · Gastroenterology · 12
[Isolation and characterization of rotavirus from bat].
2013 · Le-Le Xia, Biao He, et al. · PubMed · 8
Surveillance of CMV infection in allo-HSCT recipients and guidance on preemptive therapy by RQ-PCR.
2013 · Yan Li, Li Gao, et al. · PubMed · 6
[Clinical observation on treatment of diabetic peripheral neuphropathy by ginkgo leaf extract combined with active vitamin B12].
2004 · Wei-li Meng, Rong-jun Wang, et al. · PubMed · 6
[Urban and rural differences in aggregation risk of health risk behaviors among adolescents in Wuling Mountain Area].
2024 · Tao Xu, Jing Yu, et al. · PubMed · 3
Systematic lineage mapping uncovers polyclonal-to-monoclonal preneoplastic evolution
2023 · Lu, Zhaolian, Mo, Shanlan, et al. · Zenodo (CERN European Organization for Nuclear Research) · 3
Temporal single cell and bulk RNA sequencing data of adult mouse spinal cord after injury
2022 · Li, Chen, Wu, Zhourui, et al. · Figshare · 3
Mo1261 Characterizing the Effect of Rifaximin on Individual Symptoms of IBS-D: Findings From the Open-Label Phase of TARGET 3
2015 · Lin Chang, Mark Pimentel, et al. · Gastroenterology · 3
Effectiveness of Vitamin C Solution in Reducing Adverse Reactions Caused by Painless Lugol Chromoendoscopy
2021 · Xubiao Nie, Jianwei Ding, et al. · Journal of Clinical Gastroenterology · 2
Mo1279 Durability of Benefit in IBS-D Patients Responding to a 2-Week Course of Rifaximin: Results From TARGET 3
2015 · Mark Pimentel, Lin Chang, et al. · Gastroenterology · 2
PDF
Budesonide Foam for Inducing Remission in Active Mild-to-moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis: Results of Two Randomized, Placebo-controlled Trials
2013 · William Sandborn, Brian Bosworth, et al. · The American Journal of Gastroenterology · 2
Time to Onset and Durability of Relief in Non-Constipation IBS Patients Over 12 Weeks Following a 2-Week Course of Rifaximin
2011 · William D. Chey, Mark Pimentel, et al. · Gastroenterology · 2
PDF
U-shaped association between lymphocyte-to-high-density lipoprotein ratio and all-cause mortality in patients with chronic obstructive pulmonary disease: insights from a population-based cohort study
2025 · Yiming Ma, Zikun Fang, et al. · Journal of Thoracic Disease · 1
[Efficacy of sutureless intrascleral intraocular lens fixation with the modified Yamane technique].
2024 · Y Y Chen, D Zhou, et al. · PubMed · 1
Postoperative encapsulated hemoperitoneum in a patient with gastric stromal tumor treated by exposed endoscopic full-thickness resection: A case report
2024 · Hui-Fei Lu, Jing-Jing Li, et al. · World Journal of Gastrointestinal Surgery · 1
PDF
Preparing an adult mouse model of functional dyspepsia
2020 · Jing Yu, Pang Jiayu, et al. · Zhongguo zuzhi gongcheng yanjiu yu linchuang kangfu · 1
Mo1269 Enduring Effects Following a Course of Rifaximin Therapy in Patients With IBS-D: Incremental Benefit Upon Repeat Treatment
2015 · Brian E. Lacy, Mark Pimentel, et al. · Gastroenterology · 1
Efficacy and Tolerability of Budesonide Foam With or Without Baseline 5-Aminosalicylic Acid Use in Patients With Ulcerative Proctitis (UP) or Ulcerative Proctosigmoiditis (UPS): Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
2014 · William Sandborn, Brian Bosworth, et al. · The American Journal of Gastroenterology · 1
Works count: 48
Citation count: 1,238
H-index: 8
I10-index: 8
Year
Topic
Type